Best EPA for Heart

Top 17 products ranked · Reviewed May 2026 · 500–2000 mg clinical dose

Why EPA for Heart

EPA plays a key role in heart. EPA is the primary anti-inflammatory omega-3 fatty acid. EPA-dominant formulas (≥60% EPA) outperform DHA-dominant formulas for mood and depression in multiple meta-analyses.

What dose to look for

Clinical studies typically use 500–2000 mg of epa. 500mg minimum for general benefit; 1000-2000mg for mood/cardiovascular outcomes. Products below this range may not deliver meaningful results.

What the research says

EPA has strong clinical evidence for heart benefits. REDUCE-IT (n=8,179) showed 25% CV event reduction with pure EPA. Meta-analyses of 26 RCTs confirm EPA-dominant formulas superior for depression. Learn more

Clinical research on Omega-3 (EPA/DHA)

HIGH — Multiple large RCTs and meta-analyses · 2,000–4,000 mg/day EPA+DHA (cardioprotective doses)

•REDUCE-IT trial (2019, 8,179 patients) found 4g/day icosapent ethyl (pure EPA) reduced major cardiovascular events by 25% vs placebo in statin-treated patients with elevated triglycerides. PubMed
•VITAL trial (2019, 25,871 participants) found 1g/day omega-3 did not significantly reduce major cardiovascular events in the general population, but did reduce MI by 28% and showed greater benefit in those with low fish intake. PubMed
•2021 meta-analysis of 38 RCTs (149,051 participants) found marine omega-3 supplementation was associated with reduced risk of MI, CHD death, total CHD, and CVD death in a dose-response manner — higher doses conferred greater benefit. PubMed
•Dose matters: 1g/day (VITAL-level) shows modest benefit; 2–4g/day (REDUCE-IT level) shows substantial triglyceride reduction (20–45%) and cardiovascular risk reduction. EPA-only formulations may outperform EPA+DHA combinations.
•AHA recommends 2–4g/day EPA+DHA for triglyceride lowering. The FDA approved icosapent ethyl (Vascepa) specifically for cardiovascular risk reduction.